We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

After Celcuity (CELC) announced topline results from the PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus fulvestrant ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /CNW/ -- News Commentary – The average age of ...

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary - The average age of cancer patients is getting younger, ...

July brought major breast cancer updates, and CURE is sharing the latest, as recent developments underscore how quickly the landscape continues to evolve.

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.